回盛生物(300871.SZ)：上半年净利润1.17亿元 拟10股派1元

Core Viewpoint - The company reported significant growth in both revenue and net profit for the first half of the year, indicating strong operational performance and market demand [1] Financial Performance - The company achieved operating revenue of 822.20 million yuan, an increase of 88.45% compared to the same period last year [1] - The net profit attributable to shareholders reached 117.18 million yuan, reflecting a substantial growth of 325.88% year-on-year [1] Segment Performance - Sales revenue from chemical drug formulations increased by 54.23% year-on-year, although the gross margin decreased by 0.36% [1] - Sales revenue from veterinary raw materials surged by 199.01% compared to the previous year, with a gross margin improvement of 27.14% [1] Financial Impact - The redemption of convertible bonds led to a reduction in interest expenses by 11.31 million yuan, which had a certain impact on net profit [1] - The company declared a cash dividend of 1.00 yuan per 10 shares to all shareholders [1]